热门资讯> 正文
Veeva与安进合作加快临床试验
2025-08-28 21:30
- Veeva Systems (NYSE:VEEV) said on Thursday it is partnering with Amgen to enhance end-to-end clinical trial operations using the Veeva Clinical Platform, aiming to speed up drug development.
- "In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations which are expected to further strengthen our ability to bring innovative treatments to patients with speed and scale" Amgen CEO, Skellenger said in a statement.
- VEEV -4.63% premarket to $280.0
- Source: Press Release
More on Veeva Systems
- Veeva Systems Inc. (VEEV) Q2 2026 Earnings Call Transcript
- Veeva Systems Inc. 2026 Q2 - Results - Earnings Call Presentation
- Veeva Systems: Growth Momentum Remains Strong
- Veeva signals expanded opportunity in commercial cloud and AI following IQVIA resolution
- Veeva Systems Non-GAAP EPS of $1.99 beats by $0.09, revenue of $789.1M beats by $20.37M
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
